# Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
Canonical URL: https://biopharmsignal.com/news/IOVA/iovance-s-amtagvir-lifileucel-granted-approval-for-the-treatment-of-advanced-melanoma-in-australia
Ticker: IOVA
Company: Iovance Biotherapeutics, Inc.
Source: Iovance Biotherapeutics, Inc.
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.iovance.com
## Summary

First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on

## Article Body
First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on
## Recent Company News
- 2026-06-25 13:46 EST — [Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia](https://biopharmsignal.com/news/IOVA/iovance-s-amtagvir-lifileucel-granted-approval-for-the-treatment-of-advanced-melanoma-in-australia) — Source: Iovance Biotherapeutics, Inc.
- 2026-06-25 13:46 EST — [Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001](https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-announces-clearance-of-investigational-new-drug-ind-application-for-il-12-tethered-til-therapy-iov-5001) — Source: Iovance Biotherapeutics, Inc.
- 2026-06-25 13:46 EST — [Iovance Biotherapeutics to Present at Upcoming Conference](https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conference) — Source: Iovance Biotherapeutics, Inc.
- 2026-06-25 13:46 EST — [Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates](https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-highlights-positive-first-quarter-2026-results-business-achievements-and-corporate-updates) — Source: Iovance Biotherapeutics, Inc.
- 2026-06-25 13:46 EST — [Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma](https://biopharmsignal.com/news/IOVA/best-in-class-real-world-data-support-early-amtagvir-treatment-in-advanced-melanoma) — Source: Iovance Biotherapeutics, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)